Fountain secured $6 million Series A-1 financing from Khosla Ventures
GlobeNewswire - 19-May-2020With a total of $11 million, more in vivo preclinical drug testing to be expected
Join the club for FREE to access the whole archive and other member benefits.
Biopharmaceutical company
At Fountain Therapeutics, we have combined the expertise of leaders in aging research and computation to build a pipeline of therapeutics aimed at reversing cellular aging. Our mission is to decouple aging from disease and significantly extend human health span.
Our AI-driven platform extracts previously hidden cellular features to measure aging with remarkable precision. This has enabled us to generate unprecedented insights into the cellular aging process. We have united science, medicine and engineering to turn these insights and technologies into a powerful drug discovery and development engine for the treatment of age-related diseases.
Visit website: https://fountaintx.com/
Details last updated 29-May-2020
With a total of $11 million, more in vivo preclinical drug testing to be expected